BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

OncoMed Pharmaceuticals, Inc. 

800 Chesapeake Drive

Redwood City  California  94063  U.S.A.
Phone: 650-995-8200 Fax: 650-298-8600


SEARCH JOBS




Industry
Pharmaceutical

Segment
Start Up





 Company News
FDA Grants Orphan Drug Designations To OncoMed Pharmaceuticals, Inc. (OMED)'s Tarextumab For The Treatment Of Pancreatic And Small Cell Lung Cancer 1/29/2015 7:56:21 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The Biotechnology Industry Organization (BIO) CEO And Investor And Leerink Global Healthcare Conferences In February 1/28/2015 8:02:57 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents Final Phase 1b Safety, Efficacy And Biomarker Data For Tarextumab In Pancreatic Cancer At The 2015 Gastrointestinal Cancer Symposium 1/19/2015 7:06:38 AM
OncoMed Pharmaceuticals, Inc. (OMED) Enrolls First Biomarker-Selected Patient In Expansion Stage Of Anti-Notch1 Phase 1a Trial In Solid Tumors 1/15/2015 7:06:09 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present Clinical Data And Biomarker Analysis For Tarextumab At The 2015 Gastrointestinal Cancer Symposium 1/13/2015 7:01:13 AM
OncoMed Pharmaceuticals, Inc. (OMED) Pre-Announces 2014 Year-End Cash Balance And Provides 2015 Guidance 1/12/2015 7:27:11 AM
OncoMed Pharmaceuticals, Inc. (OMED) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/7/2015 10:12:07 AM
OncoMed Pharmaceuticals, Inc. (OMED) Doses First Patient In Phase 1 Clinical Trial Of Novel Anti-DLL4/VEGF Bispecific Antibody 1/5/2015 7:08:52 AM
OncoMed Pharmaceuticals, Inc. (OMED) Begins Patient Dosing In Phase 2 Clinical Trial of Tarextumab (Anti-Notch 2/3, OMP-59R5) in Small Cell Lung Cancer 12/1/2014 9:46:30 AM
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014 12:55:50 PM
12345678910...